Question 1

What does RxInsider cover?

Accepted Answer

RxInsider covers the business and economics of the pharmaceutical industry: M&A deals, PBM negotiations, regulatory policy, drug pipeline analysis, industry earnings, executive moves, and original pricing data. We focus on the financial mechanics and market dynamics that actually drive drug pricing and access.

Question 2

What is the difference between M&A and licensing deals?

Accepted Answer

In an M&A transaction, one company acquires another entirely, gaining all assets, liabilities, and pipeline. In a licensing deal, one company pays for rights to a specific asset (usually a drug or platform technology) while both companies remain independent. Licensing deals typically involve upfront payments plus milestone-based payments and royalties.

Question 3

How do PBM formulary negotiations work?

Accepted Answer

Pharmaceutical manufacturers compete for formulary placement by offering rebates to PBMs. Higher rebates generally earn preferred tier placement, which means lower copays for patients and higher volume for the manufacturer. PBMs use the threat of exclusion or non-preferred placement to extract larger rebates, effectively running an auction for formulary position.

Question 4

What is the IRA drug price negotiation program?

Accepted Answer

The Inflation Reduction Act (2022) gave CMS the authority to negotiate prices directly with manufacturers for certain high-spend Medicare drugs. The program selects drugs based on total Part D or Part B spending, with negotiated prices (Maximum Fair Prices) taking effect after a defined timeline. This represents the first time the US government has directly negotiated drug prices for Medicare.

Question 5

What does gross-to-net mean in pharma?

Accepted Answer

Gross-to-net is the difference between a drug list (WAC) price and the actual price realized by the manufacturer after rebates, chargebacks, discounts, and fees are deducted. For many branded drugs, the gross-to-net gap can be 50% or more, meaning the manufacturer realizes less than half the list price. This gap has been growing steadily as rebate demands increase.

Question 6

How does RxInsider source its deal intelligence?

Accepted Answer

RxInsider aggregates deal data from SEC filings, CMS disclosures, PBM contract databases, and direct industry sources. Our editorial team verifies all deal terms against primary documents before publication. We do not rely on press releases alone.

Question 7

What is the typical structure of a pharma M&A deal?

Accepted Answer

Most large pharma acquisitions include an upfront cash payment plus contingent value rights (CVRs) tied to regulatory or commercial milestones. Deal multiples typically range from 4-8x projected peak revenue for commercial-stage assets, and 15-30x for pre-revenue pipeline compounds with breakthrough potential.

Question 8

How do PBM rebate negotiations actually work?

Accepted Answer

Manufacturers submit rebate proposals to PBMs during annual formulary review cycles (typically Q3-Q4 for the following plan year). PBMs evaluate total value including base rebates, admin fees, market share guarantees, and price protection provisions. Preferred formulary position goes to the manufacturer offering the highest total rebate package in each therapeutic class.

Question 9

What drugs are included in IRA Medicare price negotiation?

Accepted Answer

CMS selected the first 10 drugs for negotiation in August 2023, including Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and insulin products. Selection criteria include Medicare Part D spend ranking, time since FDA approval (9+ years for small molecule, 13+ for biologics), and absence of generic/biosimilar competition.

Question 10

What is the typical FDA approval timeline for a new drug?

Accepted Answer

From IND filing to FDA approval, the median timeline is 10-12 years. Phase 1 averages 1-2 years, Phase 2 takes 2-3 years, Phase 3 runs 3-4 years, and the NDA/BLA review period is 10-12 months (6 months with Priority Review). Breakthrough Therapy designation can compress timelines by 2-3 years through rolling review and intensive FDA engagement.

Question 11

What is the gross-to-net bubble and why does it matter?

Accepted Answer

The gross-to-net (GTN) bubble refers to the growing gap between a drugs list price (WAC) and the actual net price received by manufacturers after rebates, discounts, chargebacks, and fees. The average GTN discount across branded drugs now exceeds 50%. This matters because it obscures real pricing trends and creates misaligned incentives throughout the supply chain.

Question 12

How do executive changes at pharma companies signal strategy shifts?

Accepted Answer

CEO transitions often signal portfolio pivots. When Pfizer hired Albert Bourla, it preceded a shift toward mRNA and oncology. When Viatris appointed a restructuring specialist, divestitures followed within 18 months. Board-level changes at PBMs tend to precede pricing model shifts or vertical integration moves. Track the background of incoming executives to predict strategic direction.

Question 13

Where does NADAC data come from and how reliable is it?

Accepted Answer

NADAC (National Average Drug Acquisition Cost) is surveyed weekly by CMS contractor Myers and Stauffer from a sample of 2,500+ retail pharmacies. It reflects actual pharmacy purchase prices, not list prices. NADAC is considered the most accurate publicly available drug pricing benchmark, though it lags real-time market changes by 1-2 weeks and does not capture hospital or specialty pharmacy pricing.

Question 14

How is the Weekly Pharma Roundup different from daily news coverage?

Accepted Answer

The weekly roundup synthesizes the 5-8 most consequential industry developments from the prior seven days with analytical context that daily coverage lacks. Rather than reporting what happened, the roundup explains why it matters: connecting a formulary change to broader PBM strategy, linking a pipeline readout to M&A probability, or tracing a policy action to its downstream pricing impact.

Question 15

Who is RxInsider written for?

Accepted Answer

Pharmaceutical industry professionals, benefits consultants, healthcare investors, PBM analysts, and policy practitioners. Our coverage assumes familiarity with industry basics and focuses on analysis rather than explanation.

Question 16

What makes RxInsider different from other pharma publications?

Accepted Answer

RxInsider focuses exclusively on the commercial mechanics of pharma: deal structures, pricing dynamics, PBM negotiations, and money flows. We do not cover clinical trial results unless they have direct commercial implications. Our audience is industry operators, not consumers.

Question 17

How do earnout provisions work in pharma licensing deals?

Accepted Answer

Licensing deals typically include an upfront payment (10-30% of total deal value), development milestones tied to IND filing, Phase 2/3 initiation, and regulatory approval, plus commercial milestones and tiered royalties on net sales (typically 10-25% depending on originator involvement).

Question 18

What is the difference between WAC, AWP, and NADAC?

Accepted Answer

WAC (Wholesale Acquisition Cost) is the manufacturers list price to wholesalers. AWP (Average Wholesale Price) is a benchmark roughly 20% above WAC, used primarily for reimbursement calculations. NADAC (National Average Drug Acquisition Cost) reflects actual pharmacy purchase prices surveyed by CMS. The spread between these benchmarks drives pharmacy economics.

Question 19

How does the IRA inflation rebate penalty work?

Accepted Answer

If a drugs price increases faster than CPI-U inflation, manufacturers must pay CMS a rebate equal to the difference multiplied by total Medicare units. This effectively caps annual Part B and Part D price increases at the inflation rate. The provision applies to all single-source drugs and biologics, not just negotiated products.

Question 20

How does biosimilar interchangeability differ from FDA approval?

Accepted Answer

FDA approval as a biosimilar allows prescribing and formulary placement, but state pharmacy laws govern automatic substitution. Interchangeable designation requires additional switching studies demonstrating no clinically meaningful differences when alternating between biosimilar and reference product. Only interchangeable biosimilars can be substituted at the pharmacy without prescriber approval.

Question 21

How do pharma companies report rebate accruals in earnings?

Accepted Answer

Manufacturers report net revenue after estimating rebate liabilities, which are accrued quarterly based on contracted rates and projected utilization. The rebate accrual estimate is one of the most judgment-intensive items on a pharma balance sheet. Accrual adjustments (favorable or unfavorable) can swing quarterly EPS by 5-15% and are closely watched by analysts.

Question 22

What is the chief pharmacy officer role in health systems?

Accepted Answer

The CPO role has expanded from drug formulary management to enterprise-level supply chain, 340B program oversight, specialty pharmacy P&L ownership, and biosimilar conversion strategy. Over 60% of large health systems now have a CPO or equivalent, up from 25% in 2018. CPOs typically report to the CMO or CFO and control drug spend budgets of $500M-2B annually.

Question 23

How should I interpret biosimilar market share data?

Accepted Answer

Biosimilar market share varies dramatically by channel. In physician-office infusion (Part B), biosimilar adalimumab adoption exceeds 50% due to ASP-based reimbursement incentives. In retail pharmacy (Part D), adoption is under 20% because PBM formulary management, not substitution, drives product selection. Always segment biosimilar share data by channel, payer type, and geography for meaningful analysis.

Question 24

What criteria determine which stories make the weekly roundup?

Accepted Answer

Stories qualify for the weekly roundup based on three criteria: (1) financial materiality exceeding $500M in deal value or market impact, (2) precedent-setting regulatory or policy action, or (3) strategic signal that changes competitive dynamics in a major therapeutic category. Routine FDA approvals, incremental data updates, and minor personnel changes are covered in section-specific coverage but not the weekly synthesis.

Question 25

How is RxInsider different from RxNews?

Accepted Answer

RxNews aggregates healthcare news from dozens of sources across the industry. RxInsider produces original analysis focused specifically on deals, negotiations, and financial dynamics. Think of RxNews as the wire service and RxInsider as the analysis desk.

FDA’s PDUFA VII tech update keeps the focus on ESG, cloud, and data standards